WO2002053590A1 - Nouvelle enzyme fibrinolytique, polynucleotide codant ce polypeptide et utilisation correspondante - Google Patents
Nouvelle enzyme fibrinolytique, polynucleotide codant ce polypeptide et utilisation correspondante Download PDFInfo
- Publication number
- WO2002053590A1 WO2002053590A1 PCT/CN2001/001631 CN0101631W WO02053590A1 WO 2002053590 A1 WO2002053590 A1 WO 2002053590A1 CN 0101631 W CN0101631 W CN 0101631W WO 02053590 A1 WO02053590 A1 WO 02053590A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- earthworm
- fibrinolytic enzyme
- plasmin
- polynucleotide
- Prior art date
Links
- 101710196208 Fibrinolytic enzyme Proteins 0.000 title claims abstract description 74
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 43
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 43
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 43
- 229920001184 polypeptide Polymers 0.000 title description 6
- 108090000765 processed proteins & peptides Proteins 0.000 title description 6
- 102000004196 processed proteins & peptides Human genes 0.000 title description 6
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 122
- 238000000034 method Methods 0.000 claims abstract description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 140
- 102000004169 proteins and genes Human genes 0.000 claims description 117
- 229940012957 plasmin Drugs 0.000 claims description 53
- 239000012634 fragment Substances 0.000 claims description 29
- 239000013598 vector Substances 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 230000004952 protein activity Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 32
- 239000000047 product Substances 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 241001233061 earthworms Species 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 230000003480 fibrinolytic effect Effects 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 12
- 239000003527 fibrinolytic agent Substances 0.000 description 12
- 239000002773 nucleotide Chemical group 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 10
- 101150069452 z gene Proteins 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000003527 eukaryotic cell Anatomy 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 150000007523 nucleic acids Chemical group 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 208000001435 Thromboembolism Diseases 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241001468653 Amynthas Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000243686 Eisenia fetida Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108091027569 Z-DNA Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- IQYRLRYAPJYANI-UHFFFAOYSA-N 2-[dodecyl(methyl)amino]acetic acid;sodium Chemical compound [Na].CCCCCCCCCCCCN(C)CC(O)=O IQYRLRYAPJYANI-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- NOTGFIUVDGNKRI-UUOKFMHZSA-N AICA ribonucleotide Chemical group NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 NOTGFIUVDGNKRI-UUOKFMHZSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101100360207 Caenorhabditis elegans rla-1 gene Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000230129 Eisenia <Phaeophyceae> Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 108010070324 lumbrokinase Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention belongs to the field of biotechnology and medicine. Specifically, the present invention relates to a novel polynucleotide encoding plasmin-earthworm plasmin Z and a protein encoded by the polynucleotide. The invention also relates to a method for preparing and using the polynucleotide and protein, and a pharmaceutical composition containing the plasmin. Background technique
- Earthworm fibrinolytic enzymes are a class of enzymes that can hydrolyze fibrin (pro) from earthworms. It is found in the digestive tract of earthworms and has a molecular weight from 15,000 to 60,000 daltons. Earthworm fibrinolytic enzymes are not a single enzyme, but a collective term for multiple proteolytic enzymes with the same function.
- earthworm fibrinolytic enzymes have dual functions. In addition to directly hydrolyzing fibrin, they can also activate plasminogen into fibrinolytic enzymes, thus indirectly hydrolyzing fibrin.
- the results of in vitro pharmacological experiments indicate that, in addition to directly dissolving blood clots, earthworm fibrinolytic enzymes can stimulate the release of tPA from vascular endothelial cells, thereby enhancing fibrinolysis in vivo.
- the results of in vivo and in vitro thrombosis model experiments and artificial thrombolysis experiments indicate that earthworm fibrinolytic enzyme has obvious antithrombotic and thrombolytic effects.
- earthworm fibrinolytic enzyme Based on the characteristics of earthworm fibrinolytic enzyme, it has been made into oral capsules at home and abroad for clinical treatment of thromboembolic diseases. For example, medicines such as Longxin, lumbrokinase, Brock, Puenfu, and thrombolytic capsules are all made from earthworm fibrinolytic enzyme. However, the structure of earthworm fibrinolytic enzymes is still unknown, and the amino acid sequence or nucleotide sequence of any specific earthworm fibrinolytic enzyme has not been reported.
- An object of the present invention is to provide a novel plasmin, earthworm plasmin, and fragments, analogs and derivatives thereof.
- Another object of the invention is to provide polynucleotides encoding these proteins.
- a novel isolated earthworm fibrinolytic enzyme Z protein is provided.
- the protein is derived from earthworms and comprises: a protein having the amino acid sequence of SEQ ID NO: 2, or a conservative variant protein thereof, or its activity Fragment, or an active derivative thereof.
- the protein has SEQ ID NO: 2 Amino acid sequence of protein.
- a polynucleotide encoding the isolated proteins, the polynucleotide comprising a nucleotide sequence having at least 70 nucleotides with a nucleotide sequence selected from the group consisting of % Homology: (a) a polynucleotide encoding the earthworm plasmin Z protein; and (b) a polynucleotide complementary to the polynucleotide (a).
- the polynucleotide encodes a protein having the amino acid sequence shown in SEQ ID NO: 2.
- sequence of the polynucleotide is one selected from the group consisting of: (a) a sequence having positions 1 to 723 in SEQ ID NO: 1; (b) a sequence having positions 1 to 979 in SEQ ID NO: 1 the sequence of.
- a method for preparing a protein having earthworm fibrinolytic enzyme z protein activity comprising: (a) culturing the above-mentioned transformed or transduced under conditions suitable for expressing earthworm fibrinolytic enzyme Z Host cells; (b) isolating a protein with earthworm fibrinolytic Z protein activity from the culture.
- an antibody that specifically binds to the earthworm fibrinolytic enzyme Z protein is provided.
- a pharmaceutical composition which contains a safe and effective amount of the earthworm plasmin Z of the present invention and a pharmaceutically acceptable carrier.
- These pharmaceutical compositions can treat conditions such as thromboembolic diseases.
- Figure 1 shows the PCR amplification bands of earthworm fibrinolytic enzyme Z.
- Lane 1 is the DNA standard;
- lane 2 is the PCR amplification product.
- Figure 2 shows the gene sequence of earthworm fibrinolytic enzyme Z and its encoded protein sequence.
- Figure 3 shows the construction process of the prokaryotic expression vector pET-28a (+) expressing earthworm fibrinolytic enzyme Z.
- Figure 4 shows the SDS-PAGE and western maps of the earthworm fibrinolytic Z expression products. The lanes are: 1. Standard molecular weight of protein, 2. Total protein of bacteria before IPTG induction, 3. Total protein of bacteria after IPTG induction, 4. Western map. detailed description
- the inventors first isolated an earthworm fibrinolysis with a molecular weight of 25125. 0 Daltons from a variety of earthworms. Enzyme (mass spectrometry results), named it earthworm fibrinolytic enzyme Z. And, with William ’s cavity g uillelini) ⁇ , the amino acid sequence at the N-terminus of earthworm fibrinolytic enzyme Z was determined, and the corresponding primers were synthesized based on this. The relevant mRNA was isolated from the earthworm as a template, and cDNA was obtained by reverse transcription. The gene of earthworm fibrinolytic enzyme Z was amplified and cloned, and the full sequence of the gene was determined.
- earthworm fibrinolytic enzyme Z was then inserted into a suitable vector and transferred into a suitable host cell, and earthworm fibrinolytic enzyme Z was expressed and isolated. And identified by Western blot analysis.
- the terms "earthworm plasmin Z”, “earthworm plasmin Z protein”, or “earthworm plasmin Z polypeptide” are used interchangeably, and all refer to having an earthworm plasmin Z amino acid sequence (SEQ ID NO: 2). They include plasmin earthworm plasmin Z with or without the starting methionine. These terms also include earthworm plasmin Z with or without a signal peptide.
- isolated refers to the separation of a substance from its original environment (if it is a natural substance, the original environment is the natural environment).
- the polynucleotide and protein in the natural state in a living cell are not separated and purified, but the same polynucleotide or protein is separated and purified if separated from other substances existing in the natural state. .
- isolated earthworm plasmin Z polypeptide or protein means that earthworm plasmin Z protein is substantially free of other proteins, lipids, sugars, or other substances with which it is naturally associated.
- Those skilled in the art can isolate and purify the earthworm fibrinolytic enzyme ⁇ using standard protein purification techniques, especially FPLC.
- the protein of the present invention may be a recombinant protein, a natural protein, or a synthetic protein, and preferably a recombinant protein.
- the protein of the present invention may be a naturally purified product or a chemically synthesized product or produced from a prokaryotic or eukaryotic host (for example, bacteria, yeast, higher plants, insects, and mammalian cells) using recombinant technology.
- a prokaryotic or eukaryotic host for example, bacteria, yeast, higher plants, insects, and mammalian cells
- the protein of the invention may be glycosylated, or it may be non-glycosylated.
- the proteins of the invention may also or may not include the initial methionine residue.
- the invention also includes fragments, derivatives and analogs of earthworm fibrinolytic enzyme Z.
- fragment refers to a protein that substantially retains the same biological function or activity of the natural earthworm fibrinolytic enzyme Z of the present invention.
- the protein fragment, derivative or analog of the present invention may be a protein in which ⁇ has one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, and such substituted amino acid residues may be It may not be encoded by the genetic code, or (ii) a protein with a substituent group in one or more amino acid residues, or (iii) a mature protein with another compound (such as a compound that extends the half-life of a protein, such as polyethylene Diol), a protein formed by fusion, or (iv) a protein formed by fusing an additional amino acid sequence to this protein sequence (such as a leader sequence or a secreted sequence or a sequence used to purify this protein or a prion sequence, or an antigen IgG Fragment of the fusion protein).
- the term "earthworm plasmin Z protein” refers to a protein of SEQ ID NO. 2 sequence having earthworm plasmin Z activity.
- the term also includes variants of the sequence of SEQ ID NO. 2 having the same function as earthworm fibrinolytic enzyme Z. These variants include (but are not limited to): several (usually 1-50, preferably 1-30, more preferably 1-20, most preferably 1-10) amino acid deletions, insertions And / or substitutions, and adding one or several (usually within 20, preferably within 10, more preferably within 5) amino acids at the C-terminus and / or N-terminus.
- substitution of amino acids with similar or similar properties usually does not change the function of the protein.
- adding one or more amino acids to the C-terminus and / or N-terminus usually does not change the function of the protein.
- the term also includes active fragments and active derivatives of earthworm fibrinolytic enzyme Z.
- Variations of this protein include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, DNA sites that can hybridize with earthworm plasmin Z DNA under high or low stringency conditions Encoded protein, and a polypeptide or protein obtained using an antiserum against earthworm plasmin Z protein.
- the present invention also provides other proteins, such as a fusion protein comprising an earthworm fibrinolytic enzyme Z protein or a fragment thereof. In addition to the almost full-length protein, the invention also includes soluble fragments of the earthworm fibrinolytic enzyme Z protein sequence.
- the fragment has at least about 10 consecutive amino acids, usually at least about 30 consecutive amino acids, preferably at least about 50 consecutive amino acids, and more preferably at least about 80 consecutive amino acids, and most preferably at least about 80 consecutive amino acids. To at least about 100 consecutive amino acids.
- the invention also provides earthworm plasmin Z or an analogue.
- the differences between these analogs and the natural earthworm fibrinolytic enzyme Z protein may be differences in amino acid sequences, differences in modified forms that do not affect the sequence, or both.
- These proteins include natural or induced genetic variants. Induced variants can be obtained by a variety of techniques, such as random mutagenesis by radiation or exposure to mutagens, or by site-directed mutagenesis or other known molecular biology techniques.
- Analogs also include analogs with residues different from natural L-amino acids (such as D-amino acids), and analogs with non-naturally occurring or synthetic amino acids (such as ⁇ , y-amino acids). It should be understood that the protein of the present invention is not limited to the representative proteins exemplified above.
- Modified (usually unchanged primary structure) forms include chemically derived forms of proteins in vivo or in vitro such as acetylation or carboxylation. Modifications also include glycosylation, such as those produced by glycosylation modification in the synthesis and processing of proteins or in further processing steps. This modification can be accomplished by exposing the protein to an enzyme that undergoes glycosylation, such as mammalian glycosylation or deglycosylation. Modified forms also include sequences having phosphorylated amino acid residues (e.g., phosphotyrosine, phosphoserine, phosphothreonine). Also included are proteins that have been modified to increase their resistance to proteolysis or to optimize their solubility.
- glycosylation such as those produced by glycosylation modification in the synthesis and processing of proteins or in further processing steps. This modification can be accomplished by exposing the protein to an enzyme that undergoes glycosylation, such as mammalian glycosylation or deglycosylation. Modified forms also include sequences having
- the "earthworm plasmin Z conservative variant protein” refers to the amino acid of SEQ ID NO: 2 Compared with sequences, there are at most 10, preferably at most 8 and more preferably at most 5 and most preferably at most 3 amino acids are replaced by amino acids with similar or similar properties to form a protein. These conservatively mutated proteins are preferably produced by amino acid substitution according to Table 1. Table 1
- the polynucleotide of the present invention may be in the form of DNA or RNA.
- DNA forms include cDNA, genomic DNA, or synthetic DNA.
- DNA can be single-stranded or double-stranded.
- DNA can be coding or non-coding.
- the coding region sequence encoding a mature protein may be the same as the coding region sequence shown in SEQ ID NO: 1 or a degenerate variant.
- a "degenerate variant" refers in the present invention to a nucleic acid sequence that encodes a protein having SEQ ID NO: 2, but which differs from the coding region sequence shown in SEQ ID NO: 1.
- the polynucleotide encoding the mature protein of SEQ ID NO: 2 includes: a coding sequence encoding only the mature protein; a coding sequence of the mature protein and various additional coding sequences; a coding sequence of the mature protein (and optional additional coding sequences); and Non-coding sequence.
- the term "polynucleotide encoding a protein" may include a polynucleotide encoding the protein, or a polynucleotide that also includes additional coding and / or non-coding sequences.
- the present invention also relates to variants of the above-mentioned polynucleotides, which encode fragments, analogs and derivatives of polypeptides or proteins having the same amino acid sequence as the present invention.
- Variants of this polynucleotide may be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants.
- an allelic variant is an alternative form of a polynucleotide that may be a substitution, deletion, or insertion of one or more nucleotides without substantially altering the function of the protein it encodes .
- the present invention also relates to a polynucleotide that hybridizes to the aforementioned sequence and has at least 50%, preferably at least 70%, and more preferably at least 80% homology between the two sequences.
- the invention particularly relates to polynucleotides that can hybridize to the polynucleotides of the invention under stringent conditions.
- “strict conditions” means: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2 X SSC, 0.1% SDS, 60 ° C ; or (2) during hybridization Added denaturing agents, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42 ° C, etc .; or (3) the homology between only two sequences is at least 90% Above, and preferably above 95%, hybridization occurs.
- the protein encoded by the hybridizable polynucleotide has the same biological function and activity as the mature protein shown in SEQ ID NO: 2.
- nucleic acid fragment that hybridizes to the sequence described above.
- a "nucleic acid fragment” has a length of at least 15 nucleotides, preferably at least 30 nucleotides, more preferably at least 50 nucleotides, and most preferably at least 100 nucleotides or more.
- Nucleic acid fragments can be used in nucleic acid amplification techniques such as PCR to identify and / or isolate polynucleotides encoding earthworm plasmin Z.
- the protein and polynucleotide in the present invention are preferably provided in an isolated form, and more preferably purified to homogeneity.
- the full-length Z-nucleotide sequence of the earthworm fibrinolytic enzyme of the present invention or a fragment thereof can usually be obtained by a PCR amplification method, a recombinant method, or a synthetic method.
- primers can be designed according to the disclosed nucleotide sequence ⁇ I, especially the open reading frame sequence, and a commercially available cDNA library or a conventional method known to those skilled in the art can be used.
- the prepared cDNA library was used as a template and amplified to obtain the relevant sequences.
- Relevant sequences can also be obtained directly by RT-PCR. When the sequence is long, it is often necessary to perform two or more PCR amplifications, and then stitch the amplified fragments together in the correct order.
- the recombination method can be used to obtain the relevant sequences in large quantities. This is usually done by cloning it into a vector, transferring it into a cell, and then isolating the relevant sequence from the proliferated host cell by conventional methods.
- relevant methods can also be synthesized by artificial synthesis, especially when the fragment length is short. Pass Often, long fragments can be obtained by first synthesizing multiple small fragments and then performing ligation.
- a DNA sequence encoding a protein (or a fragment thereof, or a derivative thereof) of the present invention can be obtained completely through chemical synthesis. This DNA sequence can then be introduced into a variety of existing DNA molecules (or such as vectors) and cells known in the art.
- mutations can also be introduced into the protein sequences of the invention by chemical synthesis.
- a method for amplifying DNA / RNA using PCR technology is preferably used to obtain the gene of the present invention.
- the RACE method RACE-cDNA terminal rapid amplification method
- the primers used for PCR may be appropriately selected based on the sequence information of the present invention disclosed herein. And can be synthesized by conventional methods.
- the amplified DNA / RNA fragments can be separated and purified by conventional methods such as by gel electrophoresis.
- the present invention also relates to a vector comprising the polynucleotide of the present invention, and a host cell genetically engineered using the vector of the present invention or earthworm plasmin Z coding sequence, and a method for producing the protein of the present invention by recombinant technology.
- the polynucleotide sequence of the present invention can be used to express or produce recombinant earthworm plasmin Z protein. Generally there are the following steps:
- the earthworm plasmin Z polynucleotide sequence can be inserted into a recombinant expression vector.
- recombinant expression vector refers to bacterial plasmids, phages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses, or other vectors well known in the art.
- Vectors suitable for use in the present invention include, but are not limited to: T7-based expression vectors expressed in bacteria; pMSXND expression vectors expressed in mammalian cells; and baculovirus-derived vectors expressed in insect cells.
- any plasmid and vector can be used as long as it can be replicated and stabilized in the host.
- An important feature of expression vectors is that they usually contain an origin of replication, a promoter, a marker gene, and translation control elements.
- Methods known to those skilled in the art can be used to construct expression vectors containing earthworm fibrinolytic enzyme Z-encoding DNA sequences and appropriate transcription / translation control signals. These methods include in vitro recombinant DNA technology, DNA synthesis technology, and in vivo recombinant technology.
- the DNA sequence can be operably linked to an appropriate promoter in an expression vector to guide mRNA synthesis. Representative examples of these promoters are: the lac or trp promoter of E.
- the expression vector also includes a ribosome binding site for translation initiation and a transcription terminator.
- the expression vector preferably contains one or more selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green for eukaryotic cell culture.
- selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase, neomycin resistance, and green for eukaryotic cell culture.
- GFP fluorescent protein
- tetracycline or ampicillin resistance for E. coli.
- a vector containing the above-mentioned appropriate DNA sequence and an appropriate promoter or control sequence can be used to transform an appropriate host cell so that it can express a protein.
- the host cell can be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell.
- a prokaryotic cell such as a bacterial cell
- a lower eukaryotic cell such as a yeast cell
- a higher eukaryotic cell such as a mammalian cell.
- Representative examples are: E. coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; plant cells; insect cells of Drosophila S2 or S 9; CHO, COS, 293 cells, or Bowes melanoma cells Animal cells and so on.
- Enhancers are cis-acting factors of DNA, usually about 10 to 300 base pairs, that act on promoters to enhance gene transcription.
- Illustrative examples include SV40 enhancers of 100 to 270 base pairs on the late side of the origin of replication, polyoma enhancers on the late side of the origin of replication, and adenoviral enhancers.
- Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art.
- the host is a prokaryote such as E. coli
- competent cells capable of DNA uptake can be harvested after exponential growth phase, with (& (: Treatment 1 2, steps well known in the art using another method is to use MgCl. 2.
- transformation can also be performed by electroporation.
- the following DNA transfection methods can be used: calcium phosphate co-precipitation method, conventional mechanical methods such as microinjection, electroporation, and lipid Body packaging, etc.
- the obtained transformants can be cultured by a conventional method to express a protein encoded by the gene of the present invention.
- the medium used in the culture may be selected from various conventional mediums. Culture is performed under conditions suitable for host cell growth. After the host cells have grown to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
- the recombinant protein in the above method may be expressed intracellularly, or on a cell membrane, or secreted extracellularly. If desired, recombinant proteins can be isolated and purified by various separation methods using their physical, chemical, and other properties. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to: conventional renaturation treatment, treatment with a protein precipitant (salting out method), centrifugation, osmotic disruption, ultra-treatment, Ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.
- Recombinant earthworm plasmin Z or protein has many uses. These uses include (but are not limited to): direct use as a drug to treat thromboembolic diseases, and to screen antibodies, proteins, or other ligands that promote or combat earthworm fibrinolytic enzyme Z function. Screening the protein library with the expressed recombinant earthworm fibrinolytic enzyme Z can be used to find therapeutic protein molecules that can inhibit or stimulate the function of earthworm fibrinolytic enzyme Z.
- the present invention also includes polyclonal antibodies and monoclonal antibodies, especially monoclonal antibodies, having specificity for the protein encoded by earthworm fibrinolytic enzyme Z DNA or fragments thereof.
- specificity means that the antibody is capable of binding to the earthworm fibrinolytic enzyme Z gene product or fragment.
- it refers to those antibodies that can bind to earthworm plasmin Z gene products or fragments but do not recognize and bind to other unrelated antigen molecules.
- the antibodies in the present invention include those molecules capable of binding and inhibiting earthworm fibrinolytic enzyme z, as well as those which do not affect the function of earthworm fibrinolytic enzyme z.
- the invention also includes those antibodies that are capable of binding to a modified or unmodified form of the earthworm plasmin Z gene product.
- the invention includes not only intact monoclonal or polyclonal antibodies, but also antibody fragments with immunological activity, such as Fab 'or (Fab) 2 fragments; antibody heavy chains; antibody light chains; genetically engineered single-chain Fv molecules; Or chimeric antibodies, such as antibodies that have murine antibody binding specificity but still retain the antibody portion from humans.
- Fab Fab 'or
- the antibodies of the present invention can be prepared by various techniques known to those skilled in the art. For example, a purified earthworm plasmin Z gene product or an antigenic fragment thereof can be administered to an animal to induce the production of polyclonal antibodies. Similarly, cells expressing earthworm plasmin Z or its antigenic fragments can be used to immunize animals to produce antibodies.
- the antibody of the present invention may be a monoclonal antibody. Such monoclonal antibodies can be prepared using hybridoma technology.
- the various antibodies of the present invention can be obtained by conventional immunological techniques using fragments or functional regions of the earthworm fibrinolytic enzyme z gene product. These fragments or functional regions can be prepared by recombinant methods or synthesized using a protein synthesizer.
- Antibodies that bind to the unmodified form of the earthworm fibrinolytic enzyme z gene product can be produced by immunizing animals with gene products produced in prokaryotic cells (for example, Co //); Phosphorylated proteins or polypeptides) can be obtained by immunizing animals with gene products produced in eukaryotic cells, such as yeast or insect cells.
- prokaryotic cells for example, Co //
- Phosphorylated proteins or polypeptides can be obtained by immunizing animals with gene products produced in eukaryotic cells, such as yeast or insect cells.
- earthworm fibrinolytic enzyme Z of the present invention through various conventional screening methods, substances that interact with the earthworm fibrinolytic enzyme Z, such as receptors, inhibitors, agonists or antagonists, can be screened.
- the earthworm fibrinolytic enzyme Z, and the antibody, inhibitor, agonist, or antagonist of the earthworm of the present invention, when administered therapeutically (administration), can provide different effects.
- these materials can be formulated in a non-toxic, inert, and pharmaceutically acceptable aqueous carrier medium, where the pH is usually about 5 to 8, preferably pH 6 to 8, although the pH can be varied with The nature of the formulation and the condition to be treated will vary.
- Formulated drug group The compounds can be administered by conventional routes including, but not limited to: intramuscular, intraperitoneal, intravenous, subcutaneous, intradermal, or local administration.
- the protein of the present invention can be directly used for the treatment of diseases, for example, for the treatment of thrombosis.
- other therapeutic agents such as antitumor drugs, can also be used simultaneously.
- the invention also provides a pharmaceutical composition containing a safe and effective amount of the earthworm fibrinolytic enzyme Z protein of the invention and a pharmaceutically acceptable carrier or excipient.
- Such carriers include (but are not limited to): saline, buffers, glucose, water, glycerol, ethanol, and combinations thereof.
- the pharmaceutical preparation should match the mode of administration.
- the pharmaceutical composition of the present invention can be prepared in the form of an injection, for example, by a conventional method using physiological saline or an aqueous solution containing glucose and other adjuvants.
- Pharmaceutical compositions such as tablets and capsules can be prepared by conventional methods.
- Pharmaceutical compositions such as injections, solutions, tablets and capsules are preferably manufactured under sterile conditions.
- the active ingredient is administered in a therapeutically effective amount, for example, from about 0.1 micrograms per kilogram body weight to about 5 milligrams per kilogram body weight per day.
- the protein of the present invention can also be used with other therapeutic agents.
- a safe and effective amount of earthworm fibrinolytic Z is administered to a mammal, wherein the safe and effective amount is usually at least about 10 micrograms / day, and in most cases not more than about 8 mg / kg body weight, Preferably the dose is from about 10 micrograms / day to about 1 mg / kg body weight.
- the specific dosage should also consider factors such as the route of administration, the patient's health, etc., which are all within the skill of a skilled physician.
- a method for detecting the presence or absence of earthworm plasmin Z in a sample is to use a specific antibody for earthworm plasmin Z, which comprises: contacting the sample with earthworm plasmin z specific antibody; and observing whether an antibody complex is formed
- the formation of an antibody complex indicates the presence of earthworm fibrinolytic enzyme z in the sample.
- the advantage of the present invention is that the earthworm contains more than 10 kinds of plasmin. It is difficult to separate and purify one of the components from earthworms to a single purity.
- the earthworm fibrinolytic enzyme z gene was cloned, its gene sequence was analyzed and determined, and it was successfully expressed.
- the earthworm fibrinolytic enzyme Z of the present invention provides a new therapeutic approach for the treatment of diseases such as thromboembolic diseases, and thus has great application prospects.
- the present invention is further described below with reference to specific embodiments. It should be understood that these examples are only used to illustrate the present invention and not to limit the scope of the present invention.
- the experimental methods without specific conditions in the following examples are usually performed according to the conventional conditions such as Sambrook et al., Molecular Cloning: Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer Suggested conditions.
- Example 1 Example 1
- peaks are isozymes of earthworm fibrinolytic enzyme, and the third peak has The most significant plasmin activity. It was dissolved in distilled water and separated and purified through multiple steps such as an ion exchange column, an affinity chromatography column, and a molecular sieve column to obtain a purified sample of earthworm fibrinolytic enzyme. The samples were analyzed by HPLC or SDS electrophoresis and showed a single band. Then, the molecular weight of the earthworm fibrinolytic enzyme was measured by mass spectrometry, and the result was 25125. 0 Dalton. The enzyme is named earthworm fibrinolytic enzyme Z. The four earthworms tested contained this earthworm fibrinolytic enzyme Z, which indicates that earthworm fibrinolytic enzyme Z is a ubiquitous fibrinolytic enzyme.
- Example 2
- the upstream oligonucleotide primer was designed as: 5'ATGAATCCATGATC C TGGGAG (T) GG (ATC) ACG (ACT) A (GC) A3 '(SEQ ID NO:
- the supernatant was aspirated into a new centrifuge tube, and 0.4 mL of 2 mol / L NaAc, Ph 4.0, 4 mL of water-saturated phenol and 2 mL of chloroform: isoamyl alcohol (49: 1) were added. After shaking, the solution was ice-baked for 15 min. Centrifuge at 10,000g at 4 ° C for 20min. Take the upper aqueous phase and mix with an equal volume of isopropanol, and leave it at -20 ° C for 1 h. 4 ° C, 10,000 g centrifugation for 20 minutes to collect the precipitate.
- the precipitate was re-dissolved in 2 mL of solution D, and incubated for 2 to 3 rain, to make it fully dissolved, 0.2 mL 2 mol / L NaAc, pH 4.0 and 2 mL isopropyl Alcohol, mix for 1 h at -20 ° C. 4 ° ⁇ , 10, 00 (centrifugation 2 (1 ⁇ 2), the precipitate was washed with 75% ethanol, and left open in the air for several minutes to fully evaporate the ethanol. Finally dissolved in DEPC (diethyl pyrocarbonate) treatment Take 30 ⁇ of sterile water. Take 1 ⁇ to measure the RNA's 0D 26 / 0D 28. , ⁇ ⁇ take formaldehyde denaturing electrophoresis to determine the purity and integrity of the RNA.
- DEPC diethyl pyrocarbonate
- RNA of William's columbaria vermicularis prepared in Example 4 was used as a template, and 3'RACE KIT was used for reverse transcription by Bowringman Company. The operation was performed according to the instructions.
- the primers synthesized in Example 3 were used for PCR amplification from the cDNA obtained above as a template.
- the total reaction system was 50 ⁇ , where the final concentration of MgCl 2 was 1.5 m mol / L, and the final concentration of dNTP was 20 ⁇ mol / L.
- the concentration of the primer was 30 n mol / L, and the unit of Tagase 2 (purchased from Gibco BRL) ).
- the reaction conditions are: denaturation at 94 ° C for 3 min, and then entering the cycle.
- the amplified nucleic acid is an unknown sequence, in order to avoid the occurrence of coincident restriction sites inside the gene, which may cause the gene to be cleaved and destroy its integrity, a T-vector was used for cloning.
- T-carrier the vector pBluescript-SK (purchased from Stratagene) was cut with ⁇ : oRI, equal volume of phenol: chloroform treatment, ethanol precipitation, dissolved in 50 ⁇ system, containing lOxPCR buffer 5 ⁇ , lOOra mol / L ⁇ 2 ⁇ , Taq enzyme 1 unit. Incubate at 70 ° C for 2h, treat with an equal volume of phenol: chloroform. After ethanol precipitation, dissolve in 10 ⁇ l sterilized water.
- a male New Zealand big-eared rabbit weighing about 2 kg was taken.
- the 1mg earthworm plasmin Z sample was ground into latex with Freund's complete adjuvant, and injected at multiple points in the rabbit's core. After half a month's rearing, the sample was ground into latex with lmg earthworm plasmin Z sample and Freund's incomplete adjuvant, and then injected into the rabbit's core at multiple points.
- 1.5 mg earthworm plasmin Z sample plus Freund's incomplete adjuvant was used to boost immunity in the same way.
- Half a month later another 1 mg of earthworm plasmin Z plus Freund's incomplete adjuvant was used to boost the immunity again. After half a month of breeding, blood was collected from the arterioles, left at 4 ° C overnight, and centrifuged at 2,000 rpm for 3 minutes. The upper serum is rabbit anti-earthworm plasmin Z antibody.
- the positive clones obtained in Example 6 were entrusted to Shanghai Ji Kang Biotechnology Company for determination.
- the complete gene sequence and the encoded protein sequence are shown in Figure 2.
- the gene is shown in SEQ ID NO: 1, and has a length of 924 bp, with a reading frame length of 723 bp (positions 1-723), and encodes 241 amino acids (SEQ ID NO: 2).
- the 3′-untranslated region after 723 bp has two polyA tail signals AATAAA.
- the earthworm plasmin Z cDNA encodes a protein sequence that is 54% homologous to a protein encoded by another cDNA called Uwibricus bi mast us. Therefore, this is a new unreported earthworm plasmin gene. From the amino acid sequence encoded by this new gene, the molecular weight calculated by computer software DNASTAR is 25138. 10, which is consistent with the molecular weight of plasmin Z extracted from earthworms.
- the translation region of the gene was expressed in the prokaryotic expression vector pET-28a (+) (Novagen), and was prepared in Example 7 Western blot analysis of rabbit anti-earthworm fibrinolytic enzyme ⁇ antibody and expression products.
- the plasmid construction map is shown in Figure 3, and the expression results are shown in Figure 4.
- the upstream primer was 5'GCGAATTCATCCTGGGAGGGACGAAA3 '(primer 3) (SEQ ID NO: 4), and the downstream primer Is: 5'CACTCGAGTTAGTGCAGTCGGCTCCA3 '(primer 4) (SEQ ID NO: 5).
- the full-length cDNA was used as a template, and PCR amplification was performed as described above.
- the amplified product fcoRlAttoI was digested and cloned into the 0 RlA1 ⁇ 2oI site of pET-28a (+).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001377825A CN1194087C (zh) | 2000-12-29 | 2000-12-29 | 蚯蚓纤溶酶z、其编码序列及用途 |
CN00137782.5 | 2000-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002053590A1 true WO2002053590A1 (fr) | 2002-07-11 |
Family
ID=4597818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2001/001631 WO2002053590A1 (fr) | 2000-12-29 | 2001-12-14 | Nouvelle enzyme fibrinolytique, polynucleotide codant ce polypeptide et utilisation correspondante |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1194087C (fr) |
WO (1) | WO2002053590A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100355884C (zh) * | 2005-01-12 | 2007-12-19 | 华东理工大学 | 一种蚯蚓纤溶酶及其编码序列与用途 |
CN101134951B (zh) * | 2006-12-04 | 2010-05-19 | 齐齐哈尔大学 | 一种纤溶酶的培制方法 |
CN109260231B (zh) * | 2017-07-18 | 2021-09-03 | 首都儿科研究所 | 一种蚯蚓中止咳祛痰抗炎抗微生物提取物的制备方法 |
CN113234708A (zh) * | 2021-05-10 | 2021-08-10 | 北京中医药大学 | 纤维蛋白溶解活性蛋白及其制备方法和应用、以及药物组合物和编码该蛋白的核酸 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1208770A (zh) * | 1998-06-11 | 1999-02-24 | 中国预防医学科学院病毒学研究所 | 正蚓科双胸蚓属蚯蚓纤溶酶基因核苷酸序列及其克隆方法 |
-
2000
- 2000-12-29 CN CNB001377825A patent/CN1194087C/zh not_active Expired - Fee Related
-
2001
- 2001-12-14 WO PCT/CN2001/001631 patent/WO2002053590A1/fr not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1208770A (zh) * | 1998-06-11 | 1999-02-24 | 中国预防医学科学院病毒学研究所 | 正蚓科双胸蚓属蚯蚓纤溶酶基因核苷酸序列及其克隆方法 |
Non-Patent Citations (3)
Title |
---|
CHI YUJIE ET AL.: "Studies on properties and thrombolytic activity of fibrinolytic enzyme from earthworm", JOURNAL OF NORTHEAST AGRICULTURAL UNIVERSITY, vol. 30, no. 4, December 1999 (1999-12-01), pages 367 - 370 * |
XIONG YI ET AL.: "Purification and determination of partial sequence of earthworm fibrinolytic enzyme", CHINESE BIOCHEMICAL JOURNAL, vol. 13, no. 3, June 1997 (1997-06-01), pages 292 - 296 * |
ZHAO XIAOYU ET AL.: "Component analysis of fibrinolytic enzyme from earthworm", CHINESE JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 14, no. 4, August 1998 (1998-08-01), pages 407 - 411 * |
Also Published As
Publication number | Publication date |
---|---|
CN1194087C (zh) | 2005-03-23 |
CN1361280A (zh) | 2002-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002521055A (ja) | 98個のヒト分泌タンパク質 | |
JP2001524814A (ja) | 28種類のヒト分泌タンパク質 | |
JPH11514224A (ja) | 新規なヘモポエチン受容体およびそれをコードする遺伝子配列 | |
US7067301B2 (en) | Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides | |
JP2002505871A (ja) | 31個のヒト分泌タンパク質 | |
JP4084411B2 (ja) | 組換え型イヌ胃リパーゼ及び医薬組成物 | |
WO2002053590A1 (fr) | Nouvelle enzyme fibrinolytique, polynucleotide codant ce polypeptide et utilisation correspondante | |
JP3023469B2 (ja) | 糖タンパク質39遺伝子 | |
US10738092B2 (en) | Muteins of a1m lipocalin and method of production therefor | |
US6887981B2 (en) | Natural antibacterial peptide, the nucleotide sequence encoding it and the use thereof | |
EP1111054B1 (fr) | Gene de lysozyme humain, polypeptide code par celui-ci et leur procede de preparation | |
US7544485B2 (en) | Baldness related gene and the polypeptide encoded thereby, and uses | |
JP2002501378A (ja) | ヒト腫瘍関連Kazalインヒビタ | |
CN100480264C (zh) | 一种广谱抑制癌细胞生长的蚯蚓蛋白及其编码序列 | |
WO2005023868A1 (fr) | Serine protease, et nucleotides codant cette serine protease | |
WO2001038524A1 (fr) | Nouveau polypeptide, proteine humaine 21 fixatrice de calcium, de la famille s100, et polynucleotide codant pour ledit polypeptide | |
WO2001029228A1 (fr) | Nouveau polypeptide, caseine kinase humaine 48, et polynucleotide codant pour ce polypeptide | |
WO2001031024A1 (fr) | Nouveau polypeptide, threonine synthetase 71, et polynucleotide codant pour ce polypeptide | |
WO2001032699A1 (fr) | Nouveau polypeptide, nouvelle udp glucose-glycoproteine glucosyltransferase (« biohugtr »), et polynucleotide codant pour ce polypeptide | |
JPH1132783A (ja) | Hfizg53ポリヌクレオチドおよびポリペプチド | |
WO2001030818A1 (fr) | Nouveau polypeptide, proteine de liaison 33 a l'arn, et polynucleotide codant pour ce polypeptide | |
WO2001030837A1 (fr) | Nouveau polypeptide, galectine 15, et polynucleotide codant pour ce polypeptide | |
WO2001029080A1 (fr) | Nouveau polypeptide, une proteine humaine hmg-13, et polynucleotide codant pour ce polypeptide | |
WO2001031023A1 (fr) | Nouveau polypeptide, proteine precurseur humaine 25 de la nucleoproteine ii, et polynucleotide codant pour ce polypeptide | |
WO2001030823A1 (fr) | Nouveau polypeptide, proteine humaine canal circulaire 69, et polynucleotide codant pour ce polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |